A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects
Status:
Unknown status
Trial end date:
2020-10-10
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, positive drug parallel controlled clinical trial in
China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups
in a ratio of 1:1 to receive the test drug and the positive control.